Toripalimab in Metastatic Renal Collecting Duct Carcinoma: A Case Report
Case Reports in Oncology · 19.05.2026 · 19 (1) · 1005-1011
DOI: 10.1159/000552402 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 19.05.2026. Verfasst von Yi Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Affiliated Hospital of Yanbian University (Yanbian Hospital), Yanji, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Collecting duct carcinoma (CDC), a rare and highly aggressive subtype of renal cell carcinoma (RCC), is often associated with poor prognosis due to its resistance to conventional therapies. Although platinum-based chemotherapy is conventionally regarded as the first-line treatment of metastatic CDC, its clinical benefits are limited. Emerging evidence suggests that CDC shares immunophenotypic and genomic features with urothelial carcinoma, providing a rationale for investigating immune checkpoint inhibitors. Case Presentation: We report the case of a 55-year-old male patient with postoperative metastatic CDC exhibiting a urothelial carcinoma-like immunophenotype. The patient presented with gross hematuria and left flank pain, and imaging revealed a large left renal mass with regional lymph node and pulmonary metastases. Histopathology confirmed CDC, characterized by high nuclear atypia, extensive necrosis, and high Ki-67 proliferation. First-line gemcitabine-cisplatin chemotherapy was discontinued due to grade III gastrointestinal toxicity, leading to imitation of second-line treatment with toripalimab, a programmed death protein 1 (PD-1) inhibitor. The patient achieved a complete response after six cycles of toripalimab, confirmed by the complete resolution of bilateral pulmonary metastases. Immune-related adverse events were managed with temporary treatment interruption, prednisone, and L-thyroxine therapy. Currently, the patient has maintained a progression-free survival of 24 months.
Conclusion
This case demonstrates the complete response of metastatic CDC to toripalimab, despite negative PD-L1 expression. This outcome highlights the role of CD8+ T-cell infiltration and IFN-γ pathway activation within the tumor microenvironment in treatment response and the potential efficacy of PD-1 inhibition as a viable therapeutic strategy for this aggressive RCC subtype.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, The Affiliated Hospital of Yanbian University (Yanbian Hospital), Yanji, China.
- Shang TCM Pte Ltd, Singapore, Singapore.
Zitieren
APA
Wu, Y., Wang, C., Gao, S., & Li, X. (2026). Toripalimab in Metastatic Renal Collecting Duct Carcinoma: A Case Report. Case Reports in Oncology, 19(1), 1005-1011. https://doi.org/10.1159/000552402
Vancouver
Wu Y, Wang C, Gao S, Li X. Toripalimab in Metastatic Renal Collecting Duct Carcinoma: A Case Report. Case Reports in Oncology. 2026;19(1):1005-1011. doi:10.1159/000552402
BibTeX
@article{Wu2026,
author = {Wu, Yi and Wang, Chao and Gao, Shuang and Li, Xiaogang},
title = {Toripalimab in Metastatic Renal Collecting Duct Carcinoma: A Case Report},
journal = {Case Reports in Oncology},
year = {2026},
volume = {19},
number = {1},
pages = {1005--1011},
doi = {10.1159/000552402}
}
EUVIMED